MAP3K19 Is a Novel Regulator of TGF-β Signaling That Impacts Bleomycin-Induced Lung Injury and Pulmonary Fibrosis

por Boehme, Stefen A., Franz-Bacon, Karin, DiTirro, Danielle N., Ly, Tai Wei, Bacon, Kevin B.
Publicado 2016

MAP3K19 Is Overexpressed in COPD and Is a Central Mediator of Cigarette Smoke-Induced Pulmonary Inflammation and Lower Airway Destruction

por Boehme, Stefen A., Franz-Bacon, Karin, Ludka, John, DiTirro, Danielle N., Ly, Tai Wei, Bacon, Kevin B.
Publicado 2016

Lysophosphatidic acid receptor 1 antagonist (EPGN2154) causes regression of NASH in preclinical NASH models

por Bhattacharjee, Jashdeep, Beaton, Graham, Ravula, Satheesh B., Lee, Suk Joong, Bacon, Kevin B., Jenkinson, Celia P., Warren, Mikako, Tucci, Fabio C., Kohli, Rohit
Publicado 2023

Targeting MAP3K19 prevents human lung myofibroblast activation both in vitro and in a humanized SCID model of idiopathic pulmonary fibrosis

por Jones, Isabelle C., Espindola, Milena S., Narayanan, Rohan, Coelho, Ana L., Habiel, David M., Boehme, Stefen A., Ly, Tai Wei, Bacon, Kevin B., Hogaboam, Cory M.
Publicado 2019

In Vivo Inhibition of CC and CX(3)C Chemokine–induced Leukocyte Infiltration and Attenuation of Glomerulonephritis in Wistar-Kyoto (WKY) Rats by vMIP-II

por Chen, Shizhong, Bacon, Kevin B., Li, Li, Garcia, Gabriela E., Xia, Yiyang, Lo, David, Thompson, Darren A., Siani, Michael A., Yamamoto, Tadashi, Harrison, Jeffrey K., Feng, Lili
Publicado 1998